Products

BioInvent develops antibody-based drugs to treat conditions where there is a significant medical need. We have a broad and innovative portfolio of therapeutic antibodies, with four products currently in preclinical and clinical development. These are aimed at the large commercial markets of thrombosis, atherosclerosis and cancer. All our products are based on novel concepts and all are protected by solid intellectual property. We have an extensive research portfolio, which feeds our development pipeline, that is built on our competence in cancer biology and inflammation. We also have long-standing relationships with academic and industrial partners that enable us to access and foster novel ideas, creating value for the Company.

We partner our products with top-class pharmaceutical or biotechnology companies with experience in commercialising antibody treatments in order to maximise the success of potential therapies. Partners have already been secured for two of BioInvent's products: the angiogenesis inhibitor, TB-403 is partnered with Roche; and the atherosclerosis treatment, BI-204 is partnered with Genentech in North America..